Iradimed Corp Financials
Iradimed Corp (IRMD) reported $83.8M in revenue for fiscal year 2025, up 14.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Stable gross margins and slower overhead growth let rising sales turn into more profit and cash without leverage.
After the prior year's inventory-heavy build, free cash flow rebounded to$17.2M even though gross margin stayed near77% , pointing to cash-conversion normalization rather than a change in product economics. That reading is reinforced because operating cash flow of$24.9M again exceeded net income of$22.5M , so reported profit and cash generation are now moving together.
Because gross margin held almost flat over the period while operating margin expanded from
The balance sheet is cash-heavy, with
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Iradimed Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Iradimed Corp has an operating margin of 31.2%, meaning the company retains $31 of operating profit per $100 of revenue. This strong profitability earns a score of 94/100, reflecting efficient cost management and pricing power. This is up from 30.0% the prior year.
Iradimed Corp's revenue grew 14.4% year-over-year to $83.8M, a solid pace of expansion. This earns a growth score of 72/100.
Iradimed Corp carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.98, Iradimed Corp holds $7.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.
Iradimed Corp converts 20.5% of revenue into free cash flow ($17.2M). This strong cash generation earns a score of 86/100.
Iradimed Corp earns a strong 23.8% return on equity (ROE), meaning it generates $24 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 89/100. This is up from 22.1% the prior year.
Iradimed Corp scores 50.57, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($14.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Iradimed Corp passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Iradimed Corp generates $1.11 in operating cash flow ($24.9M OCF vs $22.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Iradimed Corp generated $83.8M in revenue in fiscal year 2025. This represents an increase of 14.4% from the prior year.
Iradimed Corp's EBITDA was $27.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.9% from the prior year.
Iradimed Corp reported $22.5M in net income in fiscal year 2025. This represents an increase of 16.9% from the prior year.
Iradimed Corp earned $1.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 16.7% from the prior year.
Cash & Balance Sheet
Iradimed Corp generated $17.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 2.5% from the prior year.
Iradimed Corp held $51.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Iradimed Corp's gross margin was 76.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the prior year.
Iradimed Corp's operating margin was 31.2% in fiscal year 2025, reflecting core business profitability. This is up 1.2 percentage points from the prior year.
Iradimed Corp's net profit margin was 26.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.6 percentage points from the prior year.
Iradimed Corp's ROE was 23.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.6 percentage points from the prior year.
Capital Allocation
Iradimed Corp invested $3.0M in research and development in fiscal year 2025. This represents an increase of 5.0% from the prior year.
Iradimed Corp invested $7.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 3.0% from the prior year.
Not reported for fiscal year 2025.
IRMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.3M | $83.8M+14.4% | $73.2M+11.7% | $65.6M+23.0% | $53.3M+27.5% | $41.8M+31.8% | $31.7M-17.7% | $38.5M+26.5% | $30.4M+31.9% | $23.1M-29.0% | $32.5M+2.9% | $31.6M+101.8% | $15.7M+38.0% | $11.3M |
| Cost of Revenue | $20.8M | $19.5M+15.4% | $16.9M+9.7% | $15.4M+28.1% | $12.0M+23.1% | $9.8M+19.9% | $8.1M-7.6% | $8.8M+22.2% | $7.2M+29.5% | $5.6M-9.5% | $6.2M+5.4% | $5.8M+71.6% | $3.4M+19.3% | $2.9M |
| Gross Profit | $65.5M | $64.3M+14.2% | $56.4M+12.3% | $50.2M+21.5% | $41.3M+28.8% | $32.0M+36.0% | $23.6M-20.6% | $29.7M+27.9% | $23.2M+32.6% | $17.5M-33.5% | $26.3M+2.3% | $25.8M+110.3% | $12.2M+44.3% | $8.5M |
| R&D Expenses | $3.1M | $3.0M+5.0% | $2.8M-0.9% | $2.9M+25.5% | $2.3M+19.6% | $1.9M+0.1% | $1.9M+32.8% | $1.4M-5.6% | $1.5M-11.9% | $1.7M+27.8% | $1.3M-23.6% | $1.8M+65.1% | $1.1M+5.8% | $1.0M |
| SG&A Expenses | $17.3M | $17.8M+11.6% | $15.9M+5.4% | $15.1M+41.4% | $10.7M+9.5% | $9.8M-20.4% | $12.3M+17.4% | $10.5M+20.0% | $8.7M-3.2% | $9.0M+2.3% | $8.8M+13.2% | $7.8M+61.3% | $4.8M+101.4% | $2.4M |
| Operating Income | $27.6M | $26.1M+19.0% | $22.0M+9.6% | $20.0M+28.2% | $15.6M+59.2% | $9.8M+1398.5% | -$756K-108.7% | $8.6M+44.0% | $6.0M+367.2% | $1.3M-88.2% | $10.9M-5.2% | $11.5M+275.5% | $3.1M+10.0% | $2.8M |
| Income Tax | $6.7M | $5.9M+16.7% | $5.0M+10.9% | $4.5M+35.6% | $3.4M+556.3% | $511K+125.7% | -$2.0M-237.9% | -$588K-453.6% | -$106K-111.8% | $897K-76.0% | $3.7M-8.9% | $4.1M+324.5% | $967K+14.2% | $847K |
| Net Income | $23.1M | $22.5M+16.9% | $19.2M+11.9% | $17.2M+34.0% | $12.8M+37.6% | $9.3M+581.2% | $1.4M-85.8% | $9.6M+52.8% | $6.3M+1161.3% | $500K-93.1% | $7.2M-4.2% | $7.5M+267.2% | $2.1M+5.9% | $1.9M |
| EPS (Diluted) | — | $1.75+16.7% | $1.50+11.1% | $1.35+32.4% | $1.02+37.8% | $0.74+572.7% | $0.11-85.9% | $0.78+50.0% | $0.52+1200.0% | $0.04-93.3% | $0.600.0% | $0.60+200.0% | $0.20-9.1% | $0.22 |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IRMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $108.8M+10.6% | $98.3M+6.7% | $92.2M+7.8% | $85.5M+3.2% | $82.9M+16.6% | $71.1M+6.5% | $66.7M+37.7% | $48.4M+24.2% | $39.0M+4.9% | $37.2M+5.5% | $35.2M+51.2% | $23.3M+233.6% | $7.0M |
| Current Assets | $81.2M+7.9% | $75.2M-1.0% | $76.0M-1.9% | $77.5M+1.6% | $76.2M+19.6% | $63.7M+8.1% | $59.0M+32.4% | $44.5M+26.9% | $35.1M+3.7% | $33.9M-0.3% | $34.0M+53.2% | $22.2M+247.1% | $6.4M |
| Cash & Equivalents | $51.2M-2.1% | $52.2M+5.0% | $49.8M-14.1% | $58.0M-6.5% | $62.0M+23.8% | $50.1M+15.1% | $43.5M+55.1% | $28.0M+53.9% | $18.2M+2.8% | $17.7M-8.5% | $19.4M+104.9% | $9.5M+284.1% | $2.5M |
| Inventory | $11.6M+11.7% | $10.4M-18.9% | $12.8M+138.8% | $5.4M+24.9% | $4.3M+9.3% | $3.9M+8.0% | $3.6M-10.3% | $4.1M-3.6% | $4.2M+8.3% | $3.9M+63.1% | $2.4M+12.1% | $2.1M+58.6% | $1.3M |
| Accounts Receivable | $13.7M+29.5% | $10.6M-13.6% | $12.2M-7.9% | $13.3M+158.4% | $5.1M+12.3% | $4.6M-37.3% | $7.3M+73.2% | $4.2M+11.4% | $3.8M+0.1% | $3.8M-2.3% | $3.9M+97.1% | $2.0M-1.1% | $2.0M |
| Total Liabilities | $14.2M+23.0% | $11.5M-44.5% | $20.7M+75.1% | $11.8M+10.6% | $10.7M+10.6% | $9.7M-13.6% | $11.2M+72.5% | $6.5M+6.8% | $6.1M+14.6% | $5.3M+60.2% | $3.3M+36.9% | $2.4M+54.7% | $1.6M |
| Current Liabilities | $10.2M+19.6% | $8.5M-47.9% | $16.3M+90.9% | $8.6M+25.4% | $6.8M+38.8% | $4.9M-16.1% | $5.9M+24.9% | $4.7M+15.0% | $4.1M+11.4% | $3.7M+26.8% | $2.9M+26.9% | $2.3M+56.7% | $1.5M |
| Total Equity | $94.6M+9.0% | $86.8M+21.6% | $71.4M-3.1% | $73.7M+2.1% | $72.2M+17.6% | $61.4M+10.6% | $55.5M+32.4% | $41.9M+27.4% | $32.9M+3.3% | $31.9M-0.1% | $31.9M+52.9% | $20.9M+285.2% | $5.4M |
| Retained Earnings | $64.2M+13.1% | $56.8M+31.3% | $43.3M-8.5% | $47.3M+0.6% | $47.0M+24.8% | $37.7M+3.8% | $36.3M+36.1% | $26.7M+31.0% | $20.4M+2.4% | $19.9M+57.0% | $12.7M+146.9% | $5.1M+66.7% | $3.1M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
IRMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $27.1M | $24.9M-2.6% | $25.6M+90.3% | $13.5M+34.1% | $10.0M-10.8% | $11.3M+93.5% | $5.8M-43.1% | $10.2M+38.7% | $7.4M+115.9% | $3.4M-63.7% | $9.4M+23.0% | $7.6M+195.8% | $2.6M+75.4% | $1.5M |
| Capital Expenditures | $2.0M | $7.8M-3.0% | $8.0M+7.6% | $7.4M+804.1% | $823K+70.6% | $482K+8.9% | $443K+20.3% | $368K+61.3% | $228K-70.6% | $776K-0.7% | $781K+161.4% | $299K-48.8% | $584K+257.9% | $163K |
| Free Cash Flow | $25.1M | $17.2M-2.5% | $17.6M+192.5% | $6.0M-34.7% | $9.2M-14.4% | $10.8M+100.5% | $5.4M-45.5% | $9.9M+38.0% | $7.1M+170.7% | $2.6M-69.4% | $8.6M+17.3% | $7.4M+267.2% | $2.0M+52.7% | $1.3M |
| Investing Cash Flow | -$2.6M | -$8.4M+4.5% | -$8.8M-10.1% | -$8.0M-482.3% | -$1.4M-312.1% | $648K+162.5% | $247K-92.3% | $3.2M+111.2% | $1.5M+248.1% | -$1.0M+47.3% | -$1.9M-3059.0% | -$61K+99.3% | -$8.3M-4120.0% | -$197K |
| Financing Cash Flow | -$18.5M | -$17.6M-22.8% | -$14.3M-5.0% | -$13.7M-7.5% | -$12.7M-52122.1% | $24K-95.3% | $522K-74.1% | $2.0M+117.3% | $930K+148.9% | -$1.9M+79.2% | -$9.1M-492.0% | $2.3M | N/A | N/A |
| Dividends Paid | $15.8M | $15.0M+10.0% | $13.7M+3.4% | $13.2M+5.3% | $12.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.8M-81.8% | $10.0M | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IRMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.8%-0.2pp | 76.9%+0.4pp | 76.5%-0.9pp | 77.5%+0.8pp | 76.6%+2.3pp | 74.3%-2.8pp | 77.1%+0.8pp | 76.3%+0.4pp | 75.9%-5.2pp | 81.1%-0.5pp | 81.5%+3.3pp | 78.3%+3.4pp | 74.8% |
| Operating Margin | 31.2%+1.2pp | 30.0%-0.6pp | 30.6%+1.2pp | 29.3%+5.8pp | 23.5%+25.9pp | -2.4%-24.8pp | 22.4%+2.7pp | 19.7%+14.1pp | 5.6%-28.0pp | 33.6%-2.8pp | 36.4%+16.9pp | 19.6%-5.0pp | 24.6% |
| Net Margin | 26.8%+0.6pp | 26.3%0.0pp | 26.2%+2.1pp | 24.1%+1.8pp | 22.3%+18.0pp | 4.3%-20.7pp | 25.0%+4.3pp | 20.7%+18.5pp | 2.2%-20.0pp | 22.2%-1.6pp | 23.8%+10.7pp | 13.1%-4.0pp | 17.1% |
| Return on Equity | 23.8%+1.6pp | 22.1%-1.9pp | 24.1%+6.7pp | 17.4%+4.5pp | 12.9%+10.7pp | 2.2%-15.1pp | 17.3%+2.3pp | 15.0%+13.5pp | 1.5%-21.1pp | 22.6%-1.0pp | 23.6%+13.8pp | 9.8%-25.9pp | 35.7% |
| Return on Assets | 20.7%+1.1pp | 19.6%+0.9pp | 18.7%+3.7pp | 15.0%+3.7pp | 11.3%+9.3pp | 1.9%-12.5pp | 14.4%+1.4pp | 13.0%+11.7pp | 1.3%-18.1pp | 19.4%-2.0pp | 21.4%+12.6pp | 8.8%-18.9pp | 27.7% |
| Current Ratio | 7.98-0.9x | 8.84+4.2x | 4.65-4.4x | 9.06-2.1x | 11.18-1.8x | 12.96+2.9x | 10.06+0.6x | 9.50+0.9x | 8.61-0.6x | 9.25-2.5x | 11.76+2.0x | 9.74+5.3x | 4.40 |
| Debt-to-Equity | 0.150.0x | 0.13-0.2x | 0.29+0.1x | 0.160.0x | 0.150.0x | 0.160.0x | 0.200.0x | 0.150.0x | 0.180.0x | 0.17+0.1x | 0.100.0x | 0.12-0.2x | 0.29 |
| FCF Margin | 20.5%-3.6pp | 24.1%+14.9pp | 9.2%-8.1pp | 17.3%-8.5pp | 25.8%+8.8pp | 16.9%-8.7pp | 25.6%+2.1pp | 23.5%+12.0pp | 11.4%-15.1pp | 26.5%+3.3pp | 23.3%+10.5pp | 12.8%+1.2pp | 11.6% |
Similar Companies
Where Iradimed Corp Ranks
Frequently Asked Questions
What is Iradimed Corp's annual revenue?
Iradimed Corp (IRMD) reported $83.8M in total revenue for fiscal year 2025. This represents a 14.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Iradimed Corp's revenue growing?
Iradimed Corp (IRMD) revenue grew by 14.4% year-over-year, from $73.2M to $83.8M in fiscal year 2025.
Is Iradimed Corp profitable?
Yes, Iradimed Corp (IRMD) reported a net income of $22.5M in fiscal year 2025, with a net profit margin of 26.8%.
What is Iradimed Corp's EBITDA?
Iradimed Corp (IRMD) had EBITDA of $27.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Iradimed Corp's gross margin?
Iradimed Corp (IRMD) had a gross margin of 76.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Iradimed Corp's operating margin?
Iradimed Corp (IRMD) had an operating margin of 31.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Iradimed Corp's net profit margin?
Iradimed Corp (IRMD) had a net profit margin of 26.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Iradimed Corp's return on equity (ROE)?
Iradimed Corp (IRMD) has a return on equity of 23.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Iradimed Corp's free cash flow?
Iradimed Corp (IRMD) generated $17.2M in free cash flow during fiscal year 2025. This represents a -2.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Iradimed Corp's operating cash flow?
Iradimed Corp (IRMD) generated $24.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Iradimed Corp's total assets?
Iradimed Corp (IRMD) had $108.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Iradimed Corp's capital expenditures?
Iradimed Corp (IRMD) invested $7.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Iradimed Corp spend on research and development?
Iradimed Corp (IRMD) invested $3.0M in research and development during fiscal year 2025.
What is Iradimed Corp's current ratio?
Iradimed Corp (IRMD) had a current ratio of 7.98 as of fiscal year 2025, which is generally considered healthy.
What is Iradimed Corp's debt-to-equity ratio?
Iradimed Corp (IRMD) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Iradimed Corp's return on assets (ROA)?
Iradimed Corp (IRMD) had a return on assets of 20.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Iradimed Corp's Altman Z-Score?
Iradimed Corp (IRMD) has an Altman Z-Score of 50.57, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Iradimed Corp's Piotroski F-Score?
Iradimed Corp (IRMD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Iradimed Corp's earnings high quality?
Iradimed Corp (IRMD) has an earnings quality ratio of 1.11x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Iradimed Corp?
Iradimed Corp (IRMD) scores 86 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.